MyFinsight
Home
Blog
About
Cash and cash
equivalents
$44,318K
(143.24%↑ Y/Y)
Short-term investments
$34,069K
(-23.78%↓ Y/Y)
Prepaid expenses and
other current assets
$1,604K
(-65.19%↓ Y/Y)
Total current assets
$79,991K
(18.46%↑ Y/Y)
Long-term investments
$1,469K
(-82.30%↓ Y/Y)
Other assets,
long-term
$216K
Total assets
$81,676K
(7.72%↑ Y/Y)
Total liabilities and
stockholders' equity
$81,676K
(7.72%↑ Y/Y)
Total stockholders'
equity
$75,921K
(10.28%↑ Y/Y)
Total liabilities
$5,755K
(-17.59%↓ Y/Y)
Accumulated deficit
-$259,163K
(-16.28%↓ Y/Y)
Accumulated other
comprehensive (loss) gain
-$23K
(-192.00%↓ Y/Y)
Additional paid-in capital
$335,107K
(14.88%↑ Y/Y)
Total current
liabilities
$5,585K
Other non-current
liabilities
$170K
Accounts payable
$1,967K
(-6.91%↓ Y/Y)
Accrued liabilities
$1,747K
(-40.86%↓ Y/Y)
Accrued compensation
$1,095K
(-8.67%↓ Y/Y)
Other current
liabilities
$776K
(8.23%↑ Y/Y)
Back
Back
Balance Sheet
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)
source: myfinsight.com